Search Results

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”) is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference, taking place June 27, 2024.

Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2024.

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental health disorders, today reported audited financial results for its fiscal year ended March 31, 2024, and recent business highlights.

Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024.

Cybin Inc. today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled “Collaborating for Improved Mental Health.”

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones.

Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, taking place April 16-17, 2024 in Toronto, Ontario.

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry.